New brachy product begins use
The first patient has been treated with the Flexitron brachytherapy product, available from Nucletron and its developer, Isodose Control.
New brachy product begins use
The first patient has been treated with the Flexitron brachytherapy product, available from Nucletron and its developer, Isodose Control. The 40-channel afterloader was applied in the treatment of breast cancer at the Cancer Specialists of Oklahoma in Oklahoma City. Flexitron was recently integrated into Nucletron's offering of high dose rate brachytherapy afterloaders, applicators, and treatment planning solutions Sept. 1 when Nucletron and Isodose Control forged a partnership to serve the global brachytherapy marketplace. Nucletron is framing the newly introduced product as the next generation of afterloading platforms for cancer treatment. The brachytherapy product employs a 40-channel radiation delivery system with DICOM compatibility and includes dual radiation source capabilities and multiple isotope compatibility.
Large Study Affirms Safety of Ultrasound Enhancing Agents for Echocardiography
May 16th 2025Those receiving ultrasound enhancing agents (UEAs) for transthoracic or stress echocardiography had lower odds of all-cause death in comparison to patients who did not have UEAs, according to a nationwide study involving 11.4 million patients.
BrightHeart Garners Third FDA Clearance for AI-Powered Assessments of Fetal Heart Ultrasound
May 14th 2025The latest FDA 510(k) clearance is for B-Right Views, an AI-enabled device, which provides automated detection of required views necessary for second- and third-trimester fetal heart ultrasound exams.
